How cited: Koninklijke Philips Electronics N v. v. Cardiac Science Operating Co. · Go Syfert

Koninklijke Philips Electronics N v. v. Cardiac Science Operating Co. (2010)

green · 37 citation events across 11 courts. Showing the 26 strongest citers on record (one row per citing case, strongest signal kept).
All Green 26
Treatment trajectory · 2010 → 2026 · click a year to view the case as of then
201020182026
Sort: By significance · Most recent
green Robertson v. Timmermans (2010)
Rule Authority · Fed. Cir. · 3 citations in this opinion
Operating Co., 590 F.3d 1326, 1335 (Fed.
green Blue Calypso, LLC. v. Groupon, Inc. (2016)
Rule Authority · Fed. Cir. · 2 citations in this opinion
Operating Co., 590 F.3d 1326, 1336 (Fed.Cir.2010) (explaining that a fact finder "must base its analysis of written description under § 112, ¶ 1 on proper claim construction” and remanding where the district court did not construe the terms at issue); In re Katz Interactive Call Processing Patent Litig., 639 F.3d 1303, 1319 (Fed.Cir. 2011) (“claim construction is inherent in any written description analysis”), we need not determine if this was reversible error given that our…
green Shum v. Intel Corp. (2010)
Rule Authority · Fed. Cir. · 2 citations in this opinion
Operating Co., 590 F.3d 1326, 1332 (Fed.
green Lkq Corporation v. Gm Global Technology Operations LLC (2023)
Rule Authority · Fed. Cir.
Operating Co., 590 F.3d 1326, 1337 (Fed.
green Bamberg v. Dalvey (2016)
Rule Authority · Fed. Cir.
Operating Co., 590 F.3d 1326, 1334 (Fed.Cir.2010) (quoting Eli Lilly & Co. v. Bd. of Regents of the Univ. of Wash., 334 F.3d 1264, 1266 (Fed. *799 Cir.2003)).
green Xpertuniverse Inc. v. Cisco Systems, Inc. (2015)
Rule Authority · Fed. Cir.
Operating Co., 590 F.3d 1326, 1332 (Fed.Cir.2010).
green Lochner Technologies, LLC v. Vizio, Inc. (2014)
Rule Authority · Fed. Cir.
Operating Co., 590 F.3d 1326, 1336 (Fed.Cir.2010) (“A district court must base its analysis of written description under § 112, P 1 on proper claim construction.”).
green Streck, Inc. v. Research & Diagnostic Systems, Inc. (2011)
Rule Authority · Fed. Cir.
N.V. v. Cardiac *1190 Sci Operating Co., 590 F.3d 1326, 1332 (Fed.Cir.2010) (“§ 146 grants parties the right to present new testimony....”).
green Atlantic Research Marketing Systems, Inc. v. Troy (2011)
Rule Authority · Fed. Cir.
Operating Co., 590 F.3d 1326, 1336 (Fed.Cir.2010) (“A district court must base its analysis of written description under § 112, ¶ 1 on proper claim construction.”).
green Rembrandt Data Technologies, LP v. AOL, LLC (2011)
Rule Authority · Fed. Cir.
Operating Co., 590 F.3d 1326, 1332 (Fed.Cir.2010).
green AlphaVax, Inc. v. Novartis Vaccines & Diagnostics, Inc. (2010)
Rule Authority · D. Mass. · 2 citations in this opinion
N.V. v. Cardiac Science Operating Co., stating that “the Board should decide issues relating to ... patentability that are fairly raised and fully developed during the interference, despite the permissive language of § 135(a) with respect to patentability issues.” 590 F.3d 1326, 1336 (Fed.Cir.2010) (quoting In re Gartside, 203 F.3d 1305, 1317 (Fed.Cir.2000)) (emphasis in original).
green Shunock v. Apple, Inc. (2025)
Rule Authority · S.D.N.Y.
Operating Co., 590 F.3d 1326, 1336 (Fed.
green Inventist, Inc. v. Ninebot, Inc. (2021)
Rule Authority · W.D. Wash.
Operating Co., 590 F.3d 1326, 1336 (Fed.
green Sprint Communications Company L.P. v. Charter Communications, Inc. (2021)
Rule Authority · D. Del.
Operating Co., 590 F.3d 1326, 1336 (Fed.
green American Hospital Association (2018)
Rule Authority · D.D.C.
Operating Co., 590 F.3d 1326, 1332 (Fed.
quoting United States v. Grayson, 879 F.2d 620, 625 (9th Cir. 1989)
green Allergan Sales, LLC v. Sandoz, Inc. (2016)
Rule Authority · E.D. Tex.
Operating Co., 590 F.3d 1326, 1336 (Fed.Cir.2010).
green Allvoice Developments U.S., LLC v. Microsoft Corp. (2013)
Rule Authority · W.D. Wash.
N.V. v. Cardiac Science Operating, 590 F.3d 1326, 1332 (Fed.Cir.2010) (applying Ninth Circuit law to vacate sua sponte grant of summary judgment). 2 Summary judgment is appropriate if there is no genuine dispute as to any material fact and the moving party is entitled to judgment as a matter of law.
green Morningware, Inc. v. Hearthware Home Products, Inc. (2012)
Rule Authority · N.D. Ill.
Operating Co., 590 F.3d 1326, 1332 (Fed.Cir.2010)).
green Cordis Corp. v. Boston Scientific Corp. (2012)
Rule Authority · D. Del.
Operating Co., 590 F.3d 1326, 1336 (Fed.Cir.2010) (citation omitted).
green Abbott GmbH & Co. v. Centocor Ortho Biotech, Inc. (2012)
Rule Authority · D. Mass.
Operating Co., 590 F.3d 1326, 1334 (Fed.Cir.2010) (citing Perkins, 886 F.2d at 328 ).
green American Medical Systems, Inc. v. Biolitec, Inc. (2011)
Rule Authority · D. Mass.
Operating Co., 590 F.3d 1326, 1335 (Fed.Cir.2010) (quoting Rowe v. Dror, 112 F.3d 473, 479 (Fed.Cir.1997)).
green Streck, Inc. v. Research & Diagnostic Systems, Inc. (2010)
Rule Authority · D. Neb.
N.V. v. Cardiac Science Operating, 590 F.3d 1326, 1332 (Fed.Cir.2010).
green Netscape Communications Corp. v. ValueClick, Inc. (2010)
Rule Authority · E.D. Va.
Operating Co., 590 F.3d 1326, 1332 (Fed.Cir. 2010) (citation and quotation marks omitted).
citation and quotation marks omitted
green Nextec Applications v. BROOKWOOD COMPANIES, INC. (2010)
Rule Authority · S.D.N.Y.
Operating Co., 590 F.3d 1326, 1336 (Fed.Cir.2010) ("A district court must base its analysis of written description under § 112 on proper claim construction ...
green Association for Molecular Pathology v. United States Patent & Trademark Office (2010)
Cited · S.D.N.Y. · signal: see
See Koninklijke Philips Electronics N.V. v. Cardiac Science, 590 F.3d 1326, 1337 (Fed.Cir.2010) (“We remind the district court and the [USPTO] Board that they must follow judicial precedent .... ”).
green Cordance Corp. v. Amazon. Com, Inc. (2010)
Cited · D. Del. · signal: see
See Koninklijke Philips Electronics N.V. v. Cardiac Science Operating Co., 590 F.3d 1326, 1331 (Fed.Cir.2010) ("The district court should note that this court recently heard arguments en banc to consider whether § 112, P 1 contains a separate written description requirement and, if so, what the scope and purpose of that requirement should be.”) (citing ARIAD Pharms.